Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue
+27.0%
EPS
−40.3%
Free cash flow
−140.2%
Total debt
+4.46%

Quarter to September 2026, against a year earlier

25.05 0.98 −3.76%
Market cap
$7.4B
P/E
77.7×
Fwd P/E
254×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23
Total current assets
997.80 215.73 —
Total non-current assets
127.86 128.01 —
Total Assets
1,125.66 343.73 —
Total current liabilities
127.15 165.42 —
Total non-current liabilities
421.21 2,677.15 —
Total liabilities
548.36 2,842.57 —
Common Equity (Total)
577.31 (2,498.84) —
Shareholders Equity (Total)
577.31 (2,498.84) —
Total Debt
378.99 379.53 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 4 Nov 2026